Despite the recent success of immuno-oncology drugs, their use in fibrotic cancers (pancreatic, ovarian cancer) has been met with limited success. Recent research shows that Focal Adhesion Kinase (FAK) is significantly upregulated in these highly fibrotic tumours and therefore drugs targeting FAK have the potential to sensitize the tumour micro-environment to both I-O and chemotherapies. Inhibiting FAK can also directly boost the number of immune cells responsible for attacking tumours, further “amplifying” the effect of immuno-oncology treatment.
Amplia Therapeutics Limited is a pharmaceutical company advancing a pipeline of FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a “pure play” inhibitor with superior specificity. The second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways – VEGFR3 and FLT3.
- Developing small molecule drugs against Focal Adhesion Kinase (FAK) for two, significant disease areas:
- cancer – combination therapy in hard-to-treat solid tumours
- fibrosis – prevention and treatment
- Orphan Drug Designations (ODDs) for both pancreatic cancer and idiopathic pulmonary fibrosis
- Range of commercial opportunities for partnering, licensing and co-development
- First Phase 1 clinical trial starting in October 2020
- Data from Phase 1 will be relevant for multiple cancer and fibrotic disease indications
- Investigational New Drug (IND) designation and Phase 2 clinical trial program targeted in 2021